Skip to main content
Top
Published in: Osteoporosis International 4/2012

01-04-2012 | Original Article

Prevalence of osteoporosis among cancer patients in Germany

Prospective data from an oncological rehabilitation clinic

Authors: M. Reuss-Borst, U. Hartmann, C. Scheede, J. Weiß

Published in: Osteoporosis International | Issue 4/2012

Login to get access

Abstract

Summary

In this prospective study, we measured bone mineral density (BMD) in 1,041 cancer patients undergoing an oncological rehabilitation program in an inpatient rehabilitation clinic. There was an osteoporosis prevalence of approximately 16%, independent of sex, which is considerably higher than in the community-dwelling population.

Introduction

There is evidence that cancer patients are at risk of an increased BMD-loss following the disease and its therapy. Nevertheless, there is only little data available about the prevalence of osteoporosis in German cancer patients. Therefore, we measured BMD in 1,041 oncological inpatients undergoing rehabilitation.

Methods

From February 2006 to September 2009, BMD was measured in oncological patients with dual-energy x-ray absorptiometry (DXA; femur and spine). Statistical analysis for prevalence of osteoporosis was done in descriptive manner calculating means, standard deviation, frequencies, and 95% confidence intervals. To compare the prevalence of osteoporosis in different subgroups, χ 2 tests were done with p < 0.05. To create a risk profile, odds ratios were calculated using uni- and multivariate logistic regression.

Results

In 1,041 patients with a mean age of 57.1 years (11.0 years), DXA-measures were performed. Of them, 22% were male and 78% were female. The osteoporosis prevalence was about 16% (13.8, 18.2), independent of sex (p = 0.9722) or cancer type (p = 0.7174). As risk factors influencing the development of osteoporosis, age, weight, menopausal state, and hormone replacement therapy were identified in women and weight only in men.

Conclusions

Compared to the general population, the rate of osteoporosis is distinctly elevated in German cancer patients independent of sex or cancer type. Hence, a general recommendation for a DXA screening in these patients appears to be justified.
Literature
1.
go back to reference Husmann G, Kaatsch P, Katalinic A et al (2010) Krebs in Deutschland 2005/2006. Häufigkeiten und Trends. 7. Ausgabe. Robert Koch-Institut, Gesellschaft der epidemiologischen Krebsregister in Deutschland e. V. (eds.). Berlin Husmann G, Kaatsch P, Katalinic A et al (2010) Krebs in Deutschland 2005/2006. Häufigkeiten und Trends. 7. Ausgabe. Robert Koch-Institut, Gesellschaft der epidemiologischen Krebsregister in Deutschland e. V. (eds.). Berlin
2.
go back to reference Stava CJ, Jimenez C, Hu MI, Vassilopoulou-Sellin R (2009) Skeletal sequelae of cancer and cancer treatment. J Cancer Surviv 3:75–88CrossRefPubMed Stava CJ, Jimenez C, Hu MI, Vassilopoulou-Sellin R (2009) Skeletal sequelae of cancer and cancer treatment. J Cancer Surviv 3:75–88CrossRefPubMed
3.
go back to reference Brown SA, Guise TA (2009) Cancer treatment-related bone disease. Crit Rev Eukaryot Gene Expr 19:47–60PubMed Brown SA, Guise TA (2009) Cancer treatment-related bone disease. Crit Rev Eukaryot Gene Expr 19:47–60PubMed
5.
go back to reference Ito K, Elkin EB, Girotra M, Morris MJ (2010) Cost-effectiveness of fracture prevention in men who receive androgen deprivation therapy for localized prostate cancer. Ann Intern Med 152:621–629PubMed Ito K, Elkin EB, Girotra M, Morris MJ (2010) Cost-effectiveness of fracture prevention in men who receive androgen deprivation therapy for localized prostate cancer. Ann Intern Med 152:621–629PubMed
6.
go back to reference Michaud LB (2010) Managing cancer treatment-induced bone loss and osteoporosis in patients with breast or prostate cancer. Am J Health Syst Pharm 67:S20–S30CrossRefPubMed Michaud LB (2010) Managing cancer treatment-induced bone loss and osteoporosis in patients with breast or prostate cancer. Am J Health Syst Pharm 67:S20–S30CrossRefPubMed
8.
go back to reference Morote J, Morin JP, Orsola A et al (2007) Prevalence of osteoporosis during long-term androgen deprivation therapy in patients with prostate cancer. Urology 69:500–504CrossRefPubMed Morote J, Morin JP, Orsola A et al (2007) Prevalence of osteoporosis during long-term androgen deprivation therapy in patients with prostate cancer. Urology 69:500–504CrossRefPubMed
9.
go back to reference Spanik S, Spanikova B (2010) Bone mineral density in early breast cancer patients. Bratist Lek Listy 111:27–32 Spanik S, Spanikova B (2010) Bone mineral density in early breast cancer patients. Bratist Lek Listy 111:27–32
10.
go back to reference Mann GB, Kang YC, Brand C, Ebeling PR, Miller JA (2009) Secondary causes of low bone mass in patients with breast cancer: a need for greater vigilance. J Clin Oncol 27:3605–3610CrossRefPubMed Mann GB, Kang YC, Brand C, Ebeling PR, Miller JA (2009) Secondary causes of low bone mass in patients with breast cancer: a need for greater vigilance. J Clin Oncol 27:3605–3610CrossRefPubMed
11.
go back to reference Kaptoge S, da Silva JA, Brixen K et al (2008) Geographical variation in DXA bone mineral density in young European men and women. Results from the Network in Europe on Male Osteoporosis (NEMO) study. Bone 43:332–339CrossRefPubMed Kaptoge S, da Silva JA, Brixen K et al (2008) Geographical variation in DXA bone mineral density in young European men and women. Results from the Network in Europe on Male Osteoporosis (NEMO) study. Bone 43:332–339CrossRefPubMed
12.
go back to reference Tracy JK, Meyer WA, Flores RH, Wilson PD, Hochberg MC (2005) Racial differences in rate of decline in bone mass in older men: the Baltimore men's osteoporosis study. J Bone Miner Res 20:1228–1234CrossRefPubMed Tracy JK, Meyer WA, Flores RH, Wilson PD, Hochberg MC (2005) Racial differences in rate of decline in bone mass in older men: the Baltimore men's osteoporosis study. J Bone Miner Res 20:1228–1234CrossRefPubMed
13.
go back to reference Häussler B, Gothe H, Göl D, Glaeske G, Pientka L, Felsenberg D (2007) Epidemiology, treatment and costs of osteoporosis in Germany—the BoneEVA Study. Osteoporos Int 18:77–84CrossRefPubMed Häussler B, Gothe H, Göl D, Glaeske G, Pientka L, Felsenberg D (2007) Epidemiology, treatment and costs of osteoporosis in Germany—the BoneEVA Study. Osteoporos Int 18:77–84CrossRefPubMed
14.
go back to reference Michaud LB, Goodin S (2006) Cancer-treatment-induced bone loss, part 1. Am J Health Syst Pharm 63:419–430CrossRefPubMed Michaud LB, Goodin S (2006) Cancer-treatment-induced bone loss, part 1. Am J Health Syst Pharm 63:419–430CrossRefPubMed
15.
go back to reference Dachverband Osteologie e.V. (2009) DVO-Leitlinie 2009 zur Prophylaxe, Diagnostik und Therapie der Osteoporose bei Erwachsenen. Osteologie 18:304–328 Dachverband Osteologie e.V. (2009) DVO-Leitlinie 2009 zur Prophylaxe, Diagnostik und Therapie der Osteoporose bei Erwachsenen. Osteologie 18:304–328
16.
go back to reference Kanis JA, Burlet N, Cooper C, Delmas PD, Reginster JY, Borgstrom F, Rizzoli R (2008) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporosis Int 19:399–428CrossRef Kanis JA, Burlet N, Cooper C, Delmas PD, Reginster JY, Borgstrom F, Rizzoli R (2008) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporosis Int 19:399–428CrossRef
17.
18.
go back to reference Neuhouser ML, Sorensen B, Hollis BW et al (2008) Vitamin D insufficiency in a multiethnic cohort of breast cancer survivors. Am J Clin Nutr 88:133–139PubMed Neuhouser ML, Sorensen B, Hollis BW et al (2008) Vitamin D insufficiency in a multiethnic cohort of breast cancer survivors. Am J Clin Nutr 88:133–139PubMed
19.
go back to reference Crew KD, Shane E, Cremers S, McMahon DJ, Irani D, Hershman DL (2009) High prevalence of vitamin D deficiency despite supplementation in premenopausal women with breast cancer undergoing adjuvant chemotherapy. J Clin Oncol 27:2151–2156CrossRefPubMed Crew KD, Shane E, Cremers S, McMahon DJ, Irani D, Hershman DL (2009) High prevalence of vitamin D deficiency despite supplementation in premenopausal women with breast cancer undergoing adjuvant chemotherapy. J Clin Oncol 27:2151–2156CrossRefPubMed
20.
go back to reference Vashi PG, Trukova K, Lammersfeld A, Braun DP, Gupta D (2010) Impact of oral vitamin D supplementation on serum 25-hydroxyvitamin D levels in oncology. Nutr J 9:60CrossRefPubMed Vashi PG, Trukova K, Lammersfeld A, Braun DP, Gupta D (2010) Impact of oral vitamin D supplementation on serum 25-hydroxyvitamin D levels in oncology. Nutr J 9:60CrossRefPubMed
21.
go back to reference Kaptoge S, Reid DM, Scheidt-Nave C et al (2007) Geographic and other determinants of BMD change in European men and women at the hip and spine. A population-based study from the Network in Europe for Male Osteoprosis (NEMO). Bone 40:662–673CrossRefPubMed Kaptoge S, Reid DM, Scheidt-Nave C et al (2007) Geographic and other determinants of BMD change in European men and women at the hip and spine. A population-based study from the Network in Europe for Male Osteoprosis (NEMO). Bone 40:662–673CrossRefPubMed
22.
go back to reference Maghraoui AE, Ghazi M, Gassim S et al (2010) Risk factors of osteoporosis in healthy Moroccan men. BMC Musculoskelet Disord 11:148CrossRefPubMed Maghraoui AE, Ghazi M, Gassim S et al (2010) Risk factors of osteoporosis in healthy Moroccan men. BMC Musculoskelet Disord 11:148CrossRefPubMed
Metadata
Title
Prevalence of osteoporosis among cancer patients in Germany
Prospective data from an oncological rehabilitation clinic
Authors
M. Reuss-Borst
U. Hartmann
C. Scheede
J. Weiß
Publication date
01-04-2012
Publisher
Springer-Verlag
Published in
Osteoporosis International / Issue 4/2012
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-011-1724-9

Other articles of this Issue 4/2012

Osteoporosis International 4/2012 Go to the issue